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The gut mucosa is an important site of virus replication and immune activation in individuals 
infected with human immunodeficiency virus (HIV), but the impact of infection on innate 
immune cells within the gut and gut-draining mesenteric lymph nodes (LN) is ill-defined.  To 
address this gap in knowledge, we studied rhesus macaques infected with pathogenic simian 
immunodeficiency virus (SIV), which is a highly relevant model of HIV infection and AIDS.  
We analyzed macrophage, myeloid dendritic cell (mDC), and plasmacytoid dendritic cell (pDC) 
subsets in LN and terminal ileum samples taken from naive rhesus macaques and macaques 
infected with SIVmac251 with and without antiretroviral therapy (ART) to reduce virus load.  
CD163-CD68+ macrophages did not fluctuate with disease, while putative anti-inflammatory 
CD163+CD68+ macrophages were significantly increased in mesenteric and peripheral LN, 
which may be suggestive of the host’s attempt to repress inflammation.  CD11c+ mDC and 
CD123+ pDC in peripheral LN exhibited a modest decrease during acute SIV infection and 
AIDS.  Lastly, we determined the percentage of CD103+ mDC, which have been shown to 
induce regulatory T cell (Treg) differentiation in mesenteric LN and imprint Treg with gut-
homing markers.  CD103 was expressed on 31% of mDC in mesenteric LN of healthy macaques 
and a similar proportion of mDC in SIV-infected animals receiving therapy, whereas CD103+ 
mDC were depleted in untreated SIV infection, suggesting a role for CD103+ mDC loss in 
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altering Treg homeostasis.  Our results highlight the complexity of the innate immune response 
to SIV in mucosal tissues and point to contributions of macrophages and DC in virus control and 
AIDS pathogenesis.  These findings could lead to discoveries of novel innate immune 
therapeutic targets and therefore have significant public health value.   
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1.0  INTRODUCTION 
1.1 HIV-1:  EPIDEMIOLOGY 
Human immunodeficiency virus (HIV) type 1, the etiologic agent of acquired immunodeficiency 
syndrome (AIDS), infects over 34 million people worldwide with 2.7 million new cases reported 
in 2011.  Prevalence rates are highest in parts of Africa, particularly Sub-Saharan Africa, where 
67% of infected individuals reside (1, 2).  HIV is a lentivirus in the family Retroviridae with an 
RNA genome and the capacity to integrate into host DNA.  Due to the error-prone nature of its 
reverse transcriptase step during synthesis,  HIV exhibits high genomic heterogeneity that allows 
for rapid evasion of host defense mechanisms and the selection of therapy resistant mutations 
(3).  Currently, a preventative vaccine does not exist.  Today, public health efforts to stem the 
spread and morbidity of HIV/AIDS are geared primarily towards educating the public of safe sex 
practices, teaching pre-exposure prophylaxis strategies to high risk communities, and employing 
secondary prevention methods to decrease years of potential life lost (4, 5).  However, these 
efforts are costly.  In 2002, new HIV infections in the United States resulted in over $36 billion 
dollars in medical expenses and lost worker productivity (6).  Antiretroviral therapy (ART), 
commonly a cocktail of non-nucleoside reverse transcriptase inhibitors, nucleoside reserve 
transcriptase inhibitors, and protease inhibitors that directly target different stages of the viral life 
cycle, has been critical to postponing the onset of AIDS and prolonging the life expectancy of 
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HIV+ individuals (7).  Yet, despite these advances in therapy, our understanding of what drives 
HIV pathogenesis is still very limited and ultimately crucial to uncovering how to therapeutically 
minimize new infections and prevent the onset of AIDS.   
1.2 THE SIV MODEL 
Numerous animals have been used as models to forward HIV research (8).  Mice are a sensible 
animal model to study various pathogens because they are inexpensive and easy to manipulate.  
However, they are not susceptible to HIV, nor do they progress to AIDS naturally (8).  
Moreover, attempts to genetically alter or humanize mice and adapt HIV strains to mimic the 
human disease course obscure the complexities of the human immune response to HIV, making 
them unsuitable (9-11).  Other animal models, such as cats, have similar disadvantages to being 
used (12).  No perfect model exists, but at present, non-human primates have offered the best 
surrogate for HIV studies.  Rhesus macaques are non-natural hosts of the HIV simian analog, 
SIV, that progress to AIDS and develop pathologic features similar to human disease, including 
CD4+ T cell depletion and chronic immune activation.  Alternatively, SIV-infected sooty 
mangabeys and African green monkeys, each natural hosts of SIV, lack these pathologic disease 
hallmarks and therefore provide critical insight into the healthy co-existence of host and virus 
(13).  Expectedly, there are a few drawbacks to using the rhesus macaque model to study 
pathogenic infection.  One is that the SIV challenge dose typically used is much larger than the 
amount of an average human HIV exposure, therefore an assumption must be made that 
macaques and humans respond similar to infection regardless of dose (14).  A second drawback 
is that many SIV studies are conducted using cell-free virus, which does not mimic natural, cell-
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associated viral transmission (15).  Nevertheless, research conducted using non-human primates 
has contributed tremendous scientific advancements to the field and continues to be a preferable 
model for HIV studies (16).   
1.3 HIV/SIV PATHOGENESIS 
Sexual contact is the most common mode of HIV transmission, though a large number of cases 
each year occur by exposure to contaminated blood and vertically, from mother to newborn (17).  
Upon infection, HIV replication predominately takes places in CD4+ T lymphocytes, key players 
of the adaptive immune system (18).  The pathogenesis of HIV and SIV can be divided into an 
acute stage, a clinically latent stage, and AIDS.  While rhesus macaques share these disease 
stages with humans, macaques generally progress to AIDS at a more accelerated rate (19, 20).  In 
humans, acute infection manifests roughly 2-4 weeks post-exposure and is characterized by high 
plasma viremia and rapid CD4+ T cell death (17, 21).  Soon after, cytotoxic T lymphocytes of the 
adaptive immune system are mobilized to regulate the spread of virus and CD4+ T counts 
rebound slightly, establishing a period of clinical latency.  The duration of latency can differ 
dramatically from person to person depending largely on host genetics but on average lasts 10 
years without treatment (22, 23).  Overtime, however, the virus overwhelms the immune system 
putting it into a state of chronic activation.  Massive CD4+ T cell depletion and chronic immune 
activation, defined by high levels of serum pro-inflammatory cytokines and an increased 
frequency of activated T and B cells in circulation, are strong indicators of disease progression 
(24-28).  According to the Centers for Disease Control and Prevention, a clinical diagnosis of 
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AIDS is defined as CD4+ T cells falling below 200 cells/mm3 and accounting for less than 14% 
of all white blood cells and the emergence of at least one opportunistic infection (29).   
An important component of HIV/SIV pathogenesis is the dysfunction of gut immune 
homeostasis (30).  The gastrointestinal (GI) tract is both the body’s largest lymphoid organ and 
its most exposed surface to the external environment (31).  It also contains the largest reservoir 
of CD4+ T cells, which are particularly enriched in the intestinal lamina propria and gut-
associated lymphoid tissues, such as Peyer’s patches, which serve as important immune 
induction sites to the gut (32-34).  Mucosal columnar epithelial cells at the interface of the GI 
tract and lumen are home to millions of commensal microorganisms that are crucial to 
fundamental GI processes such as digestion, metabolism, and host defense (35, 36).  Figure 1 
demonstrates the structure of gut terminal ileum, a region of the small intestine with a high 
density of Peyer’s patches, taken from a rhesus macaque and stained with Hoechst dye.   
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Figure 1. Basic structural features of rhesus macaque terminal ileum.  
PFA fixed terminal ileum was sectioned to a thickness of 7µm, stained, and visualized by confocal microscopy.  
Cell nuclei (blue) are stained using membrane permeable Hoescht dye.  Image was taken at 100x magnification.   
 
Several studies have demonstrated that gut integrity is essential to the host’s ability to prevent 
pathogen infection and sustain physiological wellness (37-39).   
A signature characteristic of HIV/SIV infection that occurs during the early acute stage of 
infection regardless of transmission route is the rapid depletion of CD4+ T cells in the gut lamina 
propria.  This depletion exceeds and precedes the decline of CD4+ T cells in blood and peripheral 
LN (40, 41).  Additionally, some studies report that regulatory T cells (Treg), key modulators of 
excessive immune responses, are lost in the gut of macaques throughout the course SIV 
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infection, though contrasting evidence suggests their role in HIV/SIV infection may be unclear 
(42-47).  Microbial translocation is one proposed mechanism by which systemic, chronic 
immune activation may arise.  This proposal hypothesizes that the rapid depletion of gut CD4+ T 
cells contributes to a breakdown of the mucosal barrier causing the translocation of bacterial 
lipopolysaccharide (LPS) from the gut into circulation, which then incites persistent immune cell 
activation throughout the body (48).  Nevertheless, these crucial pieces of evidence establish the 
GI tract and mucosal immunity as a paramount target for HIV therapeutic and vaccine studies 
(14, 28, 30, 48-50).    
1.4 INNATE IMMUNITY 
Despite our growing understanding of the role of the adaptive immune response in HIV/SIV 
pathogenesis, we know less about the innate immune cells that shape that response.  Innate 
immunity is the first line of defense towards protecting the host from invading pathogens that 
have breached mechanical barriers, such as the mucosal epithelium, and is absolutely critical to 
the establishment of a healthy, antigen-specific adaptive immune response.  The innate immune 
response is rapid, antigen non-specific, and does not demonstrate immunological memory, 
though NK cells might (51-53).  NK cells, macrophages, and dendritic cells (DC) are all 
traditional sensors of the innate immune system that utilize pattern-recognition receptors, such as 
toll-like receptors (TLR), to detect conserved motifs on foreign pathogens, known as pathogen-
associated molecular patterns.  Upon activation via pattern-recognition receptor mediated 
signaling, innate immune cells mature to either eliminate the pathogen directly or communicate 
with T and B cells locally or at lymphoid induction sites via cytokine signaling and the 
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upregulation of co-stimulatory molecules to orchestrate an adaptive immune response (54).  
Antigen-presentation, the process of captured antigen being processed and presented to T cells 
underlies and begins this orchestration and thus plays an immense role in the polarization of 
adaptive immunity.  Macrophages and DC are each professional antigen-presenting cells of the 
innate immune system.  Importantly, this targeted interaction of innate and adaptive immune 
cells throughout the body is facilitated by the expression of chemokine receptors and ligands, 
which mediate cell trafficking (55, 56).   
 NK cells are innate immune lymphocytes that recognize host cells with abnormal MHC 
class I expression, typically virally infected cells, and target them for death by releasing 
cytotoxic granules.  Their role in HIV/SIV pathogenesis is not well understood, however studies 
have shown NK cells from HIV infected humans are anergic and have decreased cytotoxicity 
(57, 58).  On the contrary, some studies have suggested that NK cells may mediate antiviral 
immune pressure by favoring the selection of non-MHC class I modulatory HIV strains, 
implying their anti-viral activity is intact (59). 
Our studies here have focused on the role of the mononuclear phagocytes of the innate 
immune system (60) in SIV pathogenesis in LN and gut mucosa; specifically, macrophages, 
myeloid dendritic cells (mDC), and plasmacytoid dendritic cells (pDC).    
1.4.1 Macrophage characteristics 
Macrophages are a highly heterogeneous and plastic population of antigen-presenting cell 
derived from circulating monocytes (61, 62).  They can be found in a wide variety of tissues such 
as lung, spleen, intestine, brain, and LN, among others, and generally mature in each tissue to 
respond accordingly to the nuances of their environment (63, 64).  Classically, macrophages are 
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robust phagocytic cells that ingest foreign pathogens and cellular debris to present antigen to 
helper T cells and augment the adaptive immune response (61).  Fully polarized macrophages 
have been loosely defined as having either M1- or M2-like properties (64-66).  M1 macrophages 
promote inflammation through the secretion of IL-1β, TNF, and IL-23 and carry out microbicidal 
functions by producing factors such as reactive oxygen species.  They are differentiated in the 
presence of IFN-γ, TNF, and microbial stimuli and the absence of environmental IL-4 and IL-13, 
which act as antagonists of the M1 pathway and drive differentiation toward the M2 pathway 
(67).  M2 macrophages, in contrast to M1 macrophages, are therefore considered alternatively 
activated and are typified by their anti-inflammatory properties and ability to promote cell 
growth, angiogenesis, and tissue repair (64, 68, 69).  They express mannose receptor for 
enhanced endocytosis, are generally poor presenters of antigen to T cells, express low levels of 
the co-stimulatory molecule CD86, and have limited microbicidal activity (70, 71).   
1.4.1.1 The effects of HIV/SIV infection on macrophages  
Macrophages may be one of the first immune cells HIV infects, and similar to CD4+ T cells, they 
can serve as reservoirs for latent and infectious virus (72-75).  However, their role in HIV/SIV 
pathogenesis has been clouded by their site-specific phenotypic and functional diversity.  
CD163, CD68, HAM56, and MAC387 are some markers that have been used to describe 
macrophages in vivo and in vitro, however few HIV/SIV studies have exploited the capacity of 
these markers to delineate functionally distinct macrophage subsets (76, 77).  Hence, the role of 
the macrophage in HIV/SIV pathogenesis is likely underappreciated. 
Several macrophage subsets have been brought to attention as playing potential roles in 
HIV/SIV disease progression and immune regulation.  For example, CD163 is a transmembrane 
hemoglobin scavenger receptor that is putatively used to identify M2 macrophages (64, 68).  
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Studies have addressed the role of CD163+ macrophages in HIV-encephalitis and its simian 
analogue SIV-encephalitis (78-80).  CD163+ macrophage accumulation and productive 
replication around the perivascular cuff of the brain is reported to be partly responsible for SIV-
induced encephalopathy (81).  Furthermore, soluble CD163 is increased in the plasma of 
macaques with SIV-encephalitis (78).  In mesenteric LN, Hasegawa et al. reported that high rates 
of CD163+ macrophage turnover as indicated by an increased density of BrdU+ and TUNEL+ 
CD163+ cells was a strong predictor of disease progression (82).   
A second macrophage subtype critically involved in mucosal immunology is the intra-
intestinal lamina propria macrophage.  Because of their location, their role in HIV/SIV disease 
progression has been subject to much scrutiny.  At present, the M1/M2 paradigm is not yet 
defined with intestinal macrophages (83-85).  Functionally, intestinal macrophages have been 
characterized as highly phagocytic and inflammation anergic due to their inability to secrete pro-
inflammatory cytokines and their absence of plasma membrane LPS co-receptor CD14 (86), 
which is crucial to their co-existence with LPS-rich gut flora (85).  Moreover, they have been 
shown to be non-permissive to HIV replication (87), unlike extra-intestinal macrophages (88), 
though evidence does exist to the contrary (89).  Some studies suggest that the antigen CD68 is a 
pan-macrophage marker for many tissue macrophage subsets including macrophages of the gut 
(69, 76, 90, 91).  CD68 is a type 1 transmembrane glycoprotein located within late endosomes 
that is expressed by macrophages, monocytes, some non-myeloid cells (77), and DC precursors 
(92).  Its function is not well known.  Interestingly, based on a comparison of several reports, it 
can be inferred that the properties of intestinal macrophages do not seem to overlap with those of 
CD163+ macrophages, suggesting intestinal macrophages and CD163+ macrophages may 
potentially play unique roles in SIV pathogenesis.  
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1.4.2 mDC characteristics 
DC are critical to bridging the gap between the innate immune response and the adaptive 
immune response (93, 94).  DC are a highly diverse population of professional antigen-
presenting cell that derive from hematopoietic bone marrow progenitor cells and occupy blood 
and peripheral tissues including lungs, intestine, skin, kidneys, and LN (93).  Phenotypically, 
they can be broadly classified as CD11c+CD123- myeloid DC (mDC) or CD11c-CD123+ 
plasmacytoid DC (pDC) that are HLA-DR+ lineage (Lin)-negative (CD14-CD3-CD20-CD56-) 
(95).  mDC originate from a myeloid precursor and play a critical role in both host tolerance to 
self-antigens as well as recognition of foreign antigens (94, 96, 97).  mDC express TLR1, TLR2, 
TLR3, TLR4, TLR5, TLR6, and TLR8 for pathogen sensing and activation from an immature to 
mature status (98-101).  Antigen captured and presented by mDC, such as bacteria and viruses, 
can originate exogenously or endogenously.  Upon pathogen uptake, activated mDC migrate to 
LN where they process and present antigen peptides via MHC class II molecules to naïve T cells.  
This interaction provides the first signal towards promoting effector T cell status (99).  
Additionally, mDC communicate with cells via cytokines to influence the outcome of the 
immune response.  Which cytokines are released is determined in part by the micro-organism 
and inflammatory stimuli they encounter, ensuring that the appropriate immune response is 
mounted to protect the host (102).  Consequently, due to their potent capacity to manipulate 
adaptive immunity, mDC have been exploited to function as a vaccine to generate cell-mediated 
and humoral immunity against bacteria, viruses, and tumors (103-105).   
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1.4.3 Characteristics of CD103+ mDC and lymphocytes  
In addition to the two primary DC types, functionally specialized subsets exist (97).  CD103+ 
mDC, a subset of CD11+ mDC, have recently come to attention as critical regulators of intestinal 
immune homeostasis.  αE(CD103)β7, first described on a population of mucosally-located T 
cells, is a heterodimeric integrin molecule that binds ligand E-cadherin on epithelial cells (106).  
Studies have shown αEβ7 knock-out mice have significantly reduced intraepithelial lymphocytes 
in the gut (107).  CD103+ mDC are found primarily in intestine, colon, and mesenteric LN of 
mice and humans, and are thought to be constitutively in flux to and from these sites as 
demonstrated by studies using CCR7 deficient mice, a chemokine receptor expressed at high 
levels on this cell population (108-110).  No reports have extensively detailed CD103+ mDC in 
non-human primates.  Functionally, CD103+ mDC trigger the differentiation of Foxp3+ Treg in 
mesenteric LN and mediate trafficking of Treg, T cells, and B cells to gut mucosa (111-113).  
The expression of Foxp3, a defining determinant of Treg (114), and imprinting of gut-migratory 
markers CCR9 and α4β7 on naïve T cells are induced by CD103+ mDC secreted TGF-β and 
retinoic acid.  In addition, studies have shown TGF-β and retinoic acid produced from the 
CD103+ mDC murine analog can drive naive B cell production of IgA, an antibody isotype 
important to mucosal immunity (115).  Interestingly, CD103 signaling is not itself responsible 
for any of these mechanisms but appears to act solely as a marker for mDC endowed with the 
aforementioned properties (109). 
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1.4.4 Characteristics of CD141+ mDC 
CD141, a type 1 membrane glycoprotein, also known as thrombomodulin and BDCA-3 (116), 
denotes another specialized mDC subset of myeloid lineage (97).  The discovery of CD141+ 
mDC in humans, believed to be a functional analog of CD8α+ mDC in mice, holds a wealth of 
promise for the development of mDC-based vaccines (117-119).  The literature on this subset is 
extremely limited, but some studies suggest CD141+ mDC are Th1 polarizing cells with superior 
antigen cross-presentation activity, which is the ability to uptake and process extracellular virus 
particles using the endocytic pathway and present them by MHC class I molecules to CD8+ T 
cells (120).  CD141+ mDC also exhibit high expression of endosomal TLR3, a pattern 
recognition receptor critical to the detection of viral double-stranded RNA (121, 122).  Poly I:C 
activation of this subset has been shown to trigger robust levels of IFN-β, IL-12p70, and 
CXCL10 expression, each of which promote a shift to a more Th1-centric immune response 
(117, 121).  In addition, human blood CD141+ mDC express XCR1, a CD8+ T cell 
chemoattractant which may facilitate mDC-mediated antigen presentation (122).  CD141+ mDC 
present antigen to both CD8+ and CD4+ T cells, but to a lesser extent CD4+ T cells (121).  
Currently, there exists no literature on the function of CD141+ mDC in non-human primates, 
although they have been detected in macaque blood by flow cytometry (123, 124). 
1.4.5 pDC characteristics 
pDC derive from lymphoid precursors and function as major producers of type 1 interferons, 
specifically IFN-α, upon pathogen recognition by TLR7 and TLR9 which recognize ssRNA and 
unmethylated CpG motifs (54, 97, 101, 125).  IFN-α binds receptors on host cells triggering a 
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cascade of molecular events that culminate in the upregulation of host cellular defense 
mechanisms and enhanced function of NK cells, mDC, and T and B cells (99, 126).  pDC can 
also induce Th1 polarization and in some studies have been demonstrated to promote immune 
tolerance and regulation (127, 128).  pDC generally present antigen that originates 
endogenously, however their presentation capacity is less efficient than traditional antigen-
presenting cells due to low levels of MHC class II expression, a diminished ability to endocytose 
antigen, and the minimal presence of important antigen-presenting cell lysosomal proteases (129, 
130).  Some studies also suggest pDC are capable of antigen cross-presentation (131-134).  
Lastly, the role of pDC in immune activation due to potent IFN-α secretion has been proposed as 
an important clinical target and is currently under study (135).   
1.4.5.1 The effects of HIV/SIV infection on mDC and pDC  
mDC have been implicated in both the transmission and pathogenesis of HIV/SIV.  Several 
studies suggest HIV/SIV interacts first with intraepithelial mDC or lamina propria mDC via c-
type lectin DC-SIGN and other mechanisms like direct infection (16, 89, 136-140).  It is believed 
that mDC disseminate virus to CD4+ T cells at T cell rich lymphoid induction sites (141-146).  
This transmission facilitates the replication and spread of newly synthesized virions.  pDC have 
been shown to play a minor role in HIV/SIV transmission, possibly due to their inability to 
process and present antigen effectively and their infrequency at pathogen entry sites (125, 147), 
although they have been shown to cross-present HIV peptides to CD8+ T cells (133).  Similar to 
mDC, pDC are susceptible to HIV infection (125, 148, 149).   
In humans, mDC and pDC are well established to be lost in blood and to be functionally 
and phenotypically altered in response to HIV infection (150).  This loss, in turn, has been shown 
to correlate with an increase in viral load and disease progression (151-153).  Their roles in SIV 
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pathogenesis have been addressed in blood, peripheral LN, and to a lesser extent, the mucosa 
(154-159).  During SIV infection, mDC are reported to have decreased responsiveness to TLR 
ligand stimulation and contribute to impaired T cell function via a deficient antigen-presentation 
capacity and increased expression of B7-H1, the ligand for inhibitory molecule PD-1 which is 
upregulated on lymphocytes from SIV+ macaques (160-162).  Reports on the impact of SIV 
infection on pDC function are varied, however studies suggest pDC IFN-α production is 
hyperactive in LN and gut and may contribute to chronic immune activation (163-166).  Using 
the pathogenic SIV rhesus macaque model, our lab and others have found that mDC and pDC are 
significantly lost in blood of animals with progressive disease but not animals with stable 
infection (167).  pDC, in particular, are mobilized from bone marrow into blood and recruited to 
peripheral LN during acute infection, but die at a faster rate than they are replenished (154).  Our 
lab has also documented a loss of mDC and pDC in peripheral LN isolated from macaques with 
AIDS (155); however some studies have found otherwise (168).  A recent report found that pDC 
are lost in peripheral LN but are recruited to ileum and rectum in SIV-infected animals that 
progressed to AIDS.  Additionally, no difference in mDC proportions was found in blood, LN, or 
intestine (157).  A separate group reported an influx of pDC with increased expression of MIP-
3α, a marker for pDC migration, in the endocervix of macaques during acute stage SIV infection 
and has proposed a role for pDC in partly triggering chronic immune activation (159).   
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2.0  STATEMENT OF THE PROJECT AND SPECIFIC AIMS 
The LN and gut mucosa are important sites of inflammation during HIV/SIV replication and 
spread.  To date, knowledge of the immune response in the gut mucosa is strong in regards to 
adaptive immunity, while little focus has been placed on cells of the innate immune response.  
The purpose of this project was to better elucidate which cells of the innate immune system 
might contribute to the pathogenesis of or protection against SIV infection in LN and gut 
mucosa.  In the present study we analyzed macrophage and DC subsets in LN and gut mucosa of 
rhesus macaques pre- and post-SIV infection to determine how disease influences the dynamics 
of these cell populations.  Specifically, we used peripheral LN, mesenteric LN, and gut terminal 
ileum from archived samples to carry out these studies.  Gut-draining LN, such as mesenteric 
LN, offer an opportunity to study the impact of disease on gut immunity.  The use of peripheral 
LN, which drains extremities peripheral to the gut, complemented these studies and provided a 
picture of the peripheral immune response relative to the gut.  Understanding the emerging 
complexities of macrophage and DC subset biology may provide insight into how these cell 
types could contribute to disease control, ultimately leading to a treatment that could mimic 
natural control. 
We hypothesized that given the specialized compartmentalization of the immune system 
a) macrophages and DC in healthy rhesus macaques differentially occupy the gut and gut-
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draining mesenteric LN relative to peripheral LN and b) their proportions are differentially 
impacted by SIV as a function of infection, disease status, and ART.    
 
Aim 1: Identification of macrophage and dendritic cell subsets in lymph nodes and gut 
mucosa of healthy rhesus macaques.  Rationale:  To determine the impact of SIV disease 
status on macrophage and DC subsets in gut-draining mesenteric LN, periphery-draining 
peripheral LN, and gut, we first characterized their healthy levels in uninfected macaques.  
Hypothesis:  We hypothesized that there would be differences in the proportions of macrophage 
and DC subsets in mesenteric LN relative to peripheral LN from healthy macaques that reflect 
the compartmentalization of the immune system.  To test this hypothesis we used flow cytometry 
to quantify macrophages, mDC, CD103 and CD141 expressing mDC subsets, and pDC in 
mesenteric LN and peripheral LN from healthy rhesus macaques.  Additionally, we detected 
each cell subset in terminal ileum from uninfected macaques by immunofluorescence analysis. 
 
Aim 2: Characterize the effect of SIV infection, disease, and antiretroviral therapy on the 
proportions of macrophage and dendritic cell subsets in lymph nodes and gut mucosa.  
Rationale:  Based on the findings from Aim 1, we then mapped out the effect SIV infection and 
disease status had on the healthy-state proportions of macrophage and DC subsets.  Hypothesis:  
We hypothesized that SIV infection, disease status, and ART would differentially impact 
macrophage and DC proportions in gut and gut-draining mesenteric LN relative to peripheral 
LN.  To test this hypothesis we quantified different macrophage and DC subsets by flow 
cytometry in mesenteric and peripheral LN isolated from SIVmac251 infected rhesus macaques 
sacrificed at different stages of infection and with or without ART.  Furthermore, we performed 
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immunofluorescence staining of terminal ileum taken from SIV+ animals sacrificed at acute and 
chronic stages of infection to determine an unprocessed snapshot of macrophage and DC 
frequency during SIV infection.   
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3.0  MATERIALS AND METHODS 
3.1 ANIMAL SAMPLES 
Indian-origin rhesus macaque LN suspensions and frozen terminal ileum archived from 
published and unpublished studies were used for analyses (154-156).  Only tissue harvested at 
the day of sacrifice was used.  Table 1 provides the characteristics of each cohort.  The animals 
in this study defined as Progressor (P) and Stable (S) were prior enrolled in a vaccine study 
(169).  Briefly, they received either a control vector or an adenovirus-based vector expressing or 
not expressing IL-15 from weeks 16 to 22 and from weeks 36 to 42 post SIV inoculation.  In 
addition, each macaque received treatments of ART as specified in Table 1.  Despite boosting T 
cell responses, upon completion of the study it was ascertained that the adenovirus-based vectors 
did not have a significant impact over controls on viral load and progression to AIDS.  
Independent of the immunotherapy received, the animals enrolled in the vaccine study were 
subsequently found to separate into two groups, which we have defined as Progressor and Stable, 
based on the determinants described in Table 1.   
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Table 1. Rhesus macaque cohort characteristics. 
 
3.2 FLOW CYTOMETRY 
Cryogenically frozen LN suspensions were thawed at 37°C and then re-suspended in FACS 
buffer.  DC subsets were analyzed using CD11c-APC, CD123-PE-Cy7, CD141-PE, and CD103-
FITC antibodies.  For analysis of macrophage subsets, antibodies CD163-PerCP-Cy5.5 and 
CD68-FITC were used.  All subsets were measured as a percentage of the HLA-DR-APC-Cy7 
positive and CD20-eFluor 450 and CD3-PacBlue negative (Lin) population.  PE and FITC-
conjugated antibodies to nuclear protein Ki-67 were used to determine recently divided cells.  
CD25-PE, Foxp3-PE-Cy5, CD4-APC, and CD8-APC-Cy7 were used to identify Treg.  Further 
antibody details can be found in Table 2.  Extracellular markers CD11c, CD123, CD141, CD103, 
CD163, HLA-DR, CD20, and CD3 were applied to LN cell pellets and stained for 1 hour at 4°C 
and then washed with FACS buffer.  Next, viable cells were excluded by staining with a violet 
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fluorescent LIVE/DEAD cell stain (Invitrogen).  For analysis of intracellular antigens CD68 and 
Ki-67, following LIVE/DEAD cell stain, cells were permeabilized for 15 minutes with BD 
Cytofix/Cytoperm and then stained for 30 minutes in BD Perm/Wash buffer.  Lastly, cells were 
fixed using 2% paraformaldehyde (PFA) or Cytofix/Cytoperm in the case of intracellular antigen 
detection.  Data were acquired using a BD LSR II flow cytometer and analyzed using FlowJo 
software.  Fluorescence minus one controls were used for positive detection of each cell type.   
Table 2. Antibodies used for flow cytometric analysis of cells in LN suspensions. 
Antigen Conjugate Isotype Clone Species Company 
HLA-DR APC-Cy7 IgG2a L243 (G46-6) mouse BD 335796 
CD11c APC IgG2b S-HCL-3 mouse BD 340544 
CD123 PE-Cy7 IgG2a 7G3 mouse BD 560826 
CD163 PerCP-Cy5.5 IgG1 GH1/61 mouse  Biolegend 333608 
CD3 PacBlue IgG1 SP34-2 mouse  BD 558124 
CD141 PE IgG1 1A4 mouse BD 559781 
CD103 FITC IgG2a 2G5 mouse Beckman Coulter IM1856U 
CD68 FITC IgG1 KP1 mouse Dako F7135 
CD20 eFluor 450 IgG2b 2H7 mouse eBio 48-0209 
Ki-67 PE IgG1 B56 mouse BD 556027 
Ki-67 FITC IgG1 B56 mouse BD 556026 
CD8 APC-Cy7 IgG1 RPA-T8 mouse BD 557760 
CD4 APC IgG1 L200 mouse BD 551980 
Foxp3 PE-Cy5 IgG2a PCH101 mouse eBio 15-4776 
CD25 PE IgG1 2A3 mouse BD 341009 
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isotype APC-Cy7 IgG2a G155-178 mouse BD 557751 
isotype APC IgG2b 27-35 mouse BD 555745 
isotype PE-Cy7 IgG2a G155-178 mouse BD 552868 
isotype PerCP-Cy5.5 IgG1 MOPC-21 mouse BD 550795 
isotype PacBlue IgG1 MOPC-21 mouse BD 558120 
isotype PE IgG1 MOPC-21 mouse BD 555749 
isotype FITC IgG2a G155-178 mouse BD 555573 
isotype PE IgG1 MOPC-21 mouse BD 559320 
isotype FITC IgG1 B56 mouse BD 556026 
isotype APC-Cy7 IgG1 MOPC-21 mouse BD 557873 
isotype APC IgG1 MOPC-21 mouse BD 555751 
isotype PE-Cy5 IgG2a G155-178 mouse BD 555575 
 
3.3 IMMUNOFLUORESCENCE MICROSCOPY 
Terminal ileum and small intestine tissue isolated from rhesus macaques was fixed in 2% PFA, 
infused with 30% sucrose overnight, and then snap-frozen.  Frozen tissue was then embedded in 
OCT and sectioned to 7μm sized slices using a cryotome.  Sections were hydrated in PBS on 
Superfrost Plus(+) glass slides and then blocked for 1 hour with 10% serum matching the species 
of the secondary antibodies (goat and/or donkey serum.)  Next, endogenous peroxidase was 
quenched using 0.15% hydrogen peroxide in PBS for 10 minutes.  Sections were then incubated 
for 1.5 hours with biotinylated primary anti-human CD163 or CD123 and/or purified primary 
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anti-human CD163, CD123, CD3, or CD103 antibodies.  All staining included an appropriately 
concentrated isotype-matched IgG-antibody.  Further antibody details can be found in Table 3.  
The remaining steps were conducted in accord with the standard Tyramide Signal Amplification 
(TSA) kit protocol (Invitrogen T20932 and T20913).  TSA kits enhance the signal of target 
antigens by using an enzyme-mediated detection method that relies on the interaction of a 
horseradish peroxidase (HRP) conjugated secondary antibody with a fluorescently labeled 
Tyramide substrate.  Excluding CD3, all antigens were detected using TSA.  Following addition 
of the substrate, cells were washed in PBS and nuclei were stained for 1 minute using membrane 
permeable Hoescht dye.  Lastly, slides were mounted in gelvatol mounting medium and viewed 
on an Olympus Fluoview 1000 confocal microscope.  Representative images were selected for 
presentation and brightness adjustments were made equally to images across some figures to 
improve clarity.   
Table 3. Antibodies used for immunofluorescence analysis of cells in frozen gut tissues. 
Antigen Conjugate  Isotype Clone Species Company 
CD163 purified IgG1 5C6-FAT mouse NovusBio BM4041 
CD163 biotinylated IgG1 GHI/61 mouse eBio 13-1639 
CD123 purified IgG2a 7G3 mouse BD 554527 
CD123 biotinylated IgG2a 7G3 mouse BD 554528 
CD3 purified polyclonal - rabbit Dako A0452 
CD103 purified IgG2a 2G5.1 mouse AbD MCA70T 
isotype purified IgG1 MOPC-31C mouse  BD 550878 
isotype biotinylated IgG1 MOPC-21C mouse BD 555747 
isotype purified IgG2a X39 mouse BD 349050 
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isotype biotinylated IgG2a G155-178 mouse BD 553455 
isotype purified polyclonal - rabbit GeneTex GTX35035 
 
3.4 STATISTICAL ANALYSIS 
Statistics for all analyses were calculated using a nonparametric, two-tailed Mann-Whitney test 
with a 95% confidence interval.  A P-value <0.05 was considered significant.   
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4.0  RESULTS 
4.1 AIM 1:  IDENTIFICATION OF MACROPHAGE AND DENDRITIC CELL 
SUBSETS IN LYMPH NODES AND GUT MUCOSA OF HEALTHY RHESUS 
MACAQUES 
We used flow cytometry to determine the relative percentages of different macrophage and DC 
subsets in mesenteric and peripheral LN isolated from healthy, uninfected rhesus macaques.  A 
representative flow cytometry gating scheme for detection of each subset is depicted in Figure 2.   
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Figure 2. Representative flow cytometry gating strategy to define macrophage and DC subsets in mesenteric 
and peripheral LN. 
(A) LN cells were gated by forward and side scatter (R1) and live cells were determined based on exclusion of an 
amine reactive dye (R3).  HLA-DR+ cells and lineage (CD20, CD3) negative cells were then gated.  (B) Macrophage 
populations were subdivided into two subsets: the CD163+CD68+ subset (CD163+ macrophages) and the CD163-
CD68+ subset, which also lack dendritic cell markers.  DC subsets, mDC (CD11c+) and pDC (CD123+), were 
identified within the CD3-CD20-CD163-HLADR+ gate (R5).  (C) Detection of mDC (top panels) expressing CD103 
and CD141 and pDC (bottom panels) expressing CD103 as compared to an isotype control. 
 
Figure 3 demonstrates the proportion of each cell subset calculated as a percentage of the HLA-
DR+Lin- population (R4) from Figure 2 in healthy macaque mesenteric and peripheral LN.  A 
group size of 5 was used on most occasions, however due to the scarcity of naïve LN samples 
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available to us and human error, the size for some groups was as few as 3.  No significant 
differences were observed in the proportions of macrophages, mDC, and pDC in healthy 
mesenteric LN relative to peripheral LN from the same animals, however we observed a trend 
towards LN compartmentalization between mDC and pDC.   
 
Figure 3. Proportion of macrophages, mDC, and pDC in healthy mesenteric and peripheral LN. 
Macrophage and DC subsets from LN suspensions were gated on as described in Figure 2 and calculated as a 
percent of the HLA-DR+Lin- population (R4).  Each point represents one animal.  Horizontal lines represent means.   
 
We next determined the basal expression of CD141 and CD103 on mDC from healthy 
macaque LN.  In Figure 2 we showed by flow staining that pDC in rhesus macaques do not 
express CD103.  As of yet, we are uncertain if pDC express CD141, though studies suggests 
CD141+ DC are of myeloid origin, not lymphoid origin like pDC (97, 116).  Figure 4A is a 
representative flow plot used to determine the relative percentage of CD103 and CD141 single 
positive and double positive cells within the CD11c+ mDC population.  CD103 and CD141 were 
mostly found on two disparate populations of cells, though a small population may be double 
positive for these markers.  Next, we quantified these two mDC subsets in LN from healthy 
macaques.  In Figure 4B, we found that expression levels of CD103 and CD141 on mDC in 
mesenteric LN were significantly different relative to expression levels of CD103 and CD141 on 
mDC in peripheral LN.  Separately, CD141 was expressed on 37% of mDC in mesenteric LN 
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and 54% in peripheral LN.  Integrin CD103 was expressed on 31% of the mDC population in 
mesenteric LN and was not expressed on mDC in peripheral LN (Fig. 3B).   
 
Figure 4. Expression of CD103 and CD141 on mDC in healthy mesenteric and peripheral LN. 
mDC (CD11c+) were gated as described in Figure 2.  (A) Representative gating of CD103 and CD141 single 
positive and double positive mDC.  (B) Scatter plots demonstrate the percentage of CD103 and CD141 positive 
mDC in mesenteric and peripheral LN suspensions from healthy animals.  Each point represents one animal.  
Horizontal lines represent means and * = p<.0.05. 
   
Lastly for Aim 1, we sought to detect each subset in terminal ileum from healthy 
macaques by immunofluorescence staining.  Successful detection of CD163+ macrophages, 
CD123+ cells, and CD103+ cells is shown in Figures 5A, B, and C, respectively.   
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Figure 5. Detection of CD163+ macrophages, CD123+ cells, and CD103+ cells in healthy gut mucosa. 
Terminal ileum was sectioned and stained with anti-CD163 (A), anti-CD123 (B), and anti-CD103 and anti-CD3 (C) 
antibodies, followed by TSA detection (excluding CD3), and visualized by confocal microscopy.  White arrows 
indicate CD3-CD103+ mDC and blue arrow heads indicate CD3+CD103+ T cells (C).  Cell nuclei (blue) were stained 
with Hoechst dye (A and B).  Images were taken at 200x magnification and electronically zoomed in.  
Representative images are shown from 2-3 macaques.     
 
Fluorescent antibody staining for CD11c for mDC detection and CD141 was unsuccessful.  
Other groups have reported similar struggles identifying CD11c+ mDC by immunofluorescence 
in rhesus macaque gut tissue (140).  CD68 detection was successful but will be explored in 
future studies.  Because we were unable to detect mDC in gut and CD103 has been shown to be 
expressed exclusively on mDC and T cells in humans and mice (111), we defined mDC as 
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CD103+CD3- cells.  Figure 5C displays a population of co-labeled CD103+CD3+ T cells and 
singly labeled CD103+ cells, likely mDC.     
4.1.1 Summary of Aim 1 results 
Figures 6A and B present a holistic summary of the composition of HLA-DR+Lin- cells in 
healthy mesenteric and peripheral LN.  As described in Figure 2, each cell subset was calculated 
as a percentage of the HLA-DR+Lin- population and here is presented as a mean of several 
animals in pie graph format.  In mesenteric LN of healthy animals, as depicted in Figure 6A, we 
found mDC and pDC each represented 5% of the HLA-DR+Lin- fraction, whereas CD163+ 
macrophages represented 6% and CD163- macrophages 19%.  Figure 6B depicts the proportion 
of each subset in peripheral LN.  mDC accounted for 12% of the HLA-DR+Lin- fraction, pDC 
14%, CD163+ macrophages 7%, and CD163- macrophages 12%.     
 
Figure 6. Composition of macrophage and DC subsets in healthy mesenteric LN (A) and peripheral LN (B). 
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Macrophage and DC subsets from LN suspensions were gated on as described in Figure 2 and calculated as a 
percent of the HLADR+Lin- population (R4).  Percentages represent means from at least three healthy rhesus 
macaques.   
 
Cells labeled as undefined likely represent a variety of immature and undifferentiated 
populations.  No significant differences were observed in these cell types between the two LN 
compartments, however there was a trend towards LN compartmentalization amongst mDC and 
pDC, with fewer mDC and pDC found in mesenteric LN relative to peripheral LN.  These 
findings may suggest an immune response generated in the periphery would be more robust than 
an immune response specific to the gut.  Contrary to these results, significant differences were 
observed between CD103+ mDC and CD141+ mDC in mesenteric LN relative to CD103+ mDC 
and CD141+ mDC in peripheral LN from uninfected animals.  CD103+ mDC have gut-specific 
functions, so it is not likely they would be present in peripheral LN.  The meaning behind our 
CD141+ mDC findings is currently unclear.  Lastly, because we were unable to detect mDC and 
CD141+ cells by immunofluorescence staining, subsequent studies with terminal ileum were 
conducted only on CD163+ macrophages, CD103+ cells, and CD123+ cells. 
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4.2 AIM 2:  CHARACTERIZE THE EFFECT OF SIV INFECTION, DISEASE, AND 
ANTIRETROVIRAL THERAPY ON THE PROPORTIONS OF MACROPHAGE AND 
DENDRITIC CELL SUBSETS IN LYMPH NODES AND GUT MUCOSA. 
4.2.1 Animal cohorts and disease stages 
To determine how SIV infection, disease status, and the effect of ART impact the healthy-state 
proportions of these cell subsets, we used archived LN tissue taken from animals intravenously 
infected with SIVmac251 and sacrificed at acute (day 14), post-acute (day 36), and chronic (> 
day 36) stages of infection with or without ART to reduce viral load.  ART consisted of two 
nucleoside reverse transcriptase inhibitors (PMPA and FTC) and one protease inhibitor 
(L870812), a cocktail commonly used to suppress HIV replication in humans (170).  ART was 
administered on day 7 post-infection and continued until day 36 post-infection, the day of 
sacrifice.  Animals categorized as chronically infected were divided into two groups: those that 
progressed to AIDS status and those that stably controlled infection and did not progress to 
AIDS status as elaborated in Table 1 and defined previously (156).  In addition to flow 
cytometric analysis of mononuclear phagocyte subsets in peripheral LN and gut-draining 
mesenteric LN, immunofluorescence analysis was employed to discern the impact of infection 
and disease on macrophage and DC levels in gut mucosa.  We proceeded to analyze the impact 
of SIV infection on each cell type individually in order of macrophages, mDC, CD103+ cells, 
CD141+ mDC, and lastly, pDC.     
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4.2.2 SIV disease status impacts CD163+, but not CD163-CD68+ macrophages in LN and 
gut mucosa 
First, we sought to address the impact of SIV infection and disease on the kinetics of putative 
anti-inflammatory CD163+ macrophages and CD163- macrophages in peripheral LN, mesenteric 
LN, and terminal ileum.  We used antibodies against CD68 and CD163 to identify and 
distinguish these two populations.  Figure 7A is a representative flow plot from an uninfected 
macaque confirming the presence of these two distinct macrophage populations.   
 
Figure 7. CD163+ macrophages are increased in mesenteric and peripheral LN of acutely and progressively 
SIV-infected animals, while CD163- macrophage proportions remained unchanged between groups.   
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(A) Representative gating strategy for detection of CD163+CD68+ and CD163-CD68+ macrophages in an uninfected 
animal from the R4 population.  (B) Percentage of CD163+CD68+ macrophages in mesenteric LN (left) and 
peripheral LN (right) as determined by gating in Figure 2.  (C) Percentage of CD163-CD68+ macrophages in 
mesenteric LN (left) and peripheral LN (right) as determined by gating in Figure 2.  Each point represents one 
animal.  Horizontal lines represent means and * = p<.0.05.  UI = uninfected animal.  D14 = day 14 post SIV 
infection.  D36 = day 36 post SIV infection.  D36 +ART = animals started ART on day 7 post SIV infection and 
ended on day 36 post SIV infection.  P = animal that progressed to AIDS based on viral load.  S = animal that stably 
controlled infection based on viral load.   
 
We found that nearly 100% of CD163+ macrophages expressed CD68, a widely accepted pan-
macrophage marker (76, 91), and that a separate HLA-DR+Lin- population negative for CD163, 
CD11c, and CD123 expressed CD68, potentially LN resident macrophages (Fig. 7A, Fig. 2B) 
(76, 78, 91).   
We next addressed the impact of SIV disease status on these two macrophage subsets.  In 
Figure 7B, we found that CD163+ macrophages were significantly increased in mesenteric and 
peripheral LN of animals with acute infection as compared to LN from healthy animals.  In 
addition, we observed a significant spike in the percentage of CD163+ macrophages in 
mesenteric LN from animals that progressed to AIDS, but not in rhesus macaques that stably 
controlled infection.  Conversely, we found no statistically significant differences in CD163-
CD68+ macrophage proportions throughout infection and in response to ART compared to 
healthy control animals (Fig. 7C). 
Our findings that CD163+ macrophage proportions were increased in acutely SIV-
infected and progressor animals led us to ask whether they represented a newly mobilized 
population of macrophages.   Thus, we next used Ki-67, which is only expressed during the 
active stages of the cell cycle, to determine if these cells had recently divided.  As seen in 
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Figures 8A and B, Ki-67+CD163+ macrophages were modestly increased in peripheral and 
mesenteric LN during acute infection and significantly increased in progressively and stably 
infected macaques, and therefore may represent a recently divided population.   
 
Figure 8. Increased proliferative response of CD163+ macrophages in progressive SIV infection.   
(A) CD163+CD68+ macrophages were gated and the percentage of Ki-67 determined by comparing to staining with 
an isotype antibody.  (B) Percent of CD163+CD68+ macrophages expressing Ki-67 in the different stages of 
infection.  Each point represents one animal.  Horizontal lines represent means and * = p<0.05.  UI = uninfected 
animal.  D14 = day 14 post SIV infection.  D36 = day 36 post SIV infection.  D36 +ART = animals started ART on 
day 7 post SIV infection and ended on day 36 post SIV infection.  P = animal that progressed to AIDS based on viral 
load.  S = animal that stably controlled infection based on viral load.   
 
Next, we investigated the impact of SIV disease status on CD163+ macrophage 
proportions in terminal ileum by immunofluorescence staining.  CD163+ macrophages were 
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primarily confined to the lamina propria of the terminal ileum but could also be identified in the 
submucosa (Fig. 9).  We observed a noticeable increase in the density of CD163+ macrophages 
in Peyer’s patches from animals with chronic stage disease compared to healthy animals (Fig. 9).  
There also appeared to be a slight increase in the density of CD163+ macrophages in the lamina 
propria and submucosa of animals with acute and chronic SIV infection that was not as evident 
in terminal ileum from control animals. 
 
Figure 9. CD163+ macrophage density increases in Peyer’s patches of chronically SIV-infected macaques. 
Immunofluorescence staining with anti-CD163 antibody was performed on terminal ileum isolated from uninfected, 
acute, and chronically infected macaques.  PFA fixed tissues were sectioned to a thickness of 7µm, stained, and 
visualized by confocal microscopy.  Isotype control staining is shown in the inset.  The CD163 marker was used to 
define macrophages (green).  Cell nuclei (blue) were stained with Hoechst dye.  TSA was used to detect anti-CD163 
antibody staining.  Images were taken at 200x magnification.  Representative images are shown from 2-3 macaques 
per group.   
 
Together, these data suggest that CD163+ macrophages are being recruited to LN and gut 
Peyer’s patches during SIV infection.      
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4.2.3 mDC are modestly lost in peripheral LN during SIV infection 
mDC dynamics have been investigated in peripheral and mesenteric LN of rhesus macaques with 
acute and chronic stages of SIV infection (167).  mDC findings have been conflicting:  some 
studies suggest depletion in LN is correlated with disease progression and others report no 
significant changes or an accumulation (157, 168).   
Here we aimed to investigate the effect of SIV infection and disease status on mDC 
kinetics in peripheral and mesenteric LN.  Figure 10A shows a representative flow plot used to 
define CD11c+ mDC as compared to an isotype control.   
 
Figure 10. Proportions of mDC are modestly decreased in peripheral LN of SIV-infected macaques. 
mDC were analyzed within the HLA-DR+Lin- gate (R4) as described in Figure 2.  (A) Contour plots represent gating 
for CD11c+ mDC as compared to an isotype control.  (B) Percent mDC of total HLA-DR+Lin- cells in mesenteric 
(left) and peripheral (right) LN.  Each point represents one animal and horizontal lines represent means.  * = p<0.05.  
UI = uninfected animal.  D14 = day 14 post SIV infection.  D36 = day 36 post SIV infection.  D36 +ART = animals 
started ART on day 7 post SIV infection and ended on day 36 post SIV infection.  P = animal that progressed to 
AIDS based on viral load.  S = animal that stably controlled infection based on viral load.  
 
In mesenteric LN we found few significant deviations in mDC proportions during acute, post-
acute, or chronic stages of SIV infection as compared to healthy animals.  However, there was a 
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significant increase of mDC proportions within the HLA-DR+Lin- population in mesenteric LN 
of ART treated animals compared to untreated animals (Fig. 10B).  In contrast, mDC proportions 
exhibited a modest decrease in peripheral LN during acute and chronic SIV infection (Fig. 10B).     
From these findings, we can conclude that there is a modest loss in peripheral LN mDC 
proportions in response to SIV infection relative to no change in mDC proportions in mesenteric 
LN.   
4.2.4 CD103+ mDC are lost in mesenteric LN and gut during SIV infection, an effect not 
seen in ART treated animals  
Recently, a subset of mDC that expresses αE integrin, or CD103, has been implicated in playing 
a significant role in the differentiation and homing of Treg to mucosal sites in humans and mice 
(111).  This molecule has also been found expressed on T cells and mDC and has been reported 
to facilitate effector T cell migration to the gut (113).  Based on these reports, we first set out to 
detect the level of CD103 expression on T cells.  Figure 11A is a representative flow gating 
scheme that was used to gate CD3+ T cells and determine what proportion express CD103.  
Roughly 2% of mesenteric LN CD3+ T cells from uninfected animals expressed CD103.  
Furthermore, this percentage did not fluctuate at acute, post-acute, or chronic stages of SIV 
infection and was not altered by ART (Fig. 11B).   
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Figure 11. SIV disease status does not change the frequency of CD103+ T cells in mesenteric LN. 
The percentage of CD103+ T cells was determined in all cohorts by gating T cells as described in (A) and analyzing 
CD103 expression on the R4 population.  (B) Dot plots show one representative experiment from each cohort as 
compared to an isotype control.  UI = uninfected animal.  D14 = day 14 post SIV infection.  D36 +ART = animals 
started ART on day 7 post SIV infection and ended on day 36 post SIV infection.  P = animal that progressed to 
AIDS based on viral load.   
 
Next, we determined if CD103+ pDC and CD103+ mDC proportions are influenced by 
SIV disease status in peripheral LN, mesenteric LN, and terminal ileum from rhesus macaques.  
In Figure 12, we found less than 1% of pDC from the HLA-DR+Lin- population expressed 
CD103 in peripheral and mesenteric LN of healthy macaques, nearly equivalent to the isotype.  
We show in Figures 12A and B that this percentage does not change throughout SIV infection, 
which strongly implies that CD103 is not expressed on CD123+ cells.  
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Figure 12. pDC do not express integrin CD103. 
(A) Representative flow cytometry contour plots to depict the expression of CD103 on pDC in the different cohorts 
as compared to an isotype control.  (B) Percent of pDC expressing CD103 in the different cohorts in mesenteric 
(left) and peripheral (right) LN.  Each point represents one animal and horizontal lines represent means.  UI = 
uninfected animal.  D14 = day 14 post SIV infection.  D36 +ART = animals started ART on day 7 post SIV 
infection and ended on day 36 post SIV infection.  P = animal that progressed to AIDS based on viral load.   
 
Finally, we analyzed the impact of SIV infection and disease status on the percentage of 
CD103+ mDC in mesenteric and peripheral LN.  In mesenteric LN from naïve macaques, we 
found that roughly 31% of mDC expressed CD103.  Strikingly, as disease progressed we 
observed a near two-fold decrease of CD103+ mDC in mesenteric LN from acutely SIV-infected 
animals and an even greater decrease in chronically infected animals that was not seen in ART 
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treated animals (Fig. 13A and B).  We also observed that CD103 was not expressed on mDC in 
peripheral LN (Fig. 13B). 
 
Figure 13. CD103+ mDC are lost in mesenteric LN as SIV infection progresses, an effect not seen in ART 
treated animals. 
mDC were defined as positive for expression of CD11c as described in Figure 2B and analyzed for expression of 
CD103 (Fig. 2C).  (A) Representative flow cytometry contour plots to depict the expression of CD103 on mDC in 
the different cohorts.  (B) Each point represents the percentage of CD103+ mDC in mesenteric (left) or peripheral 
(right) LN of one animal.  Horizontal lines represent means and * = p<0.05.  UI = uninfected animal.  D14 = day 14 
post SIV infection.  D36 = day 36 post SIV infection.  D36 +ART = animals started ART on day 7 post SIV 
infection and ended on day 36 post SIV infection.  P = animal that progressed to AIDS based on viral load.  S = 
animal that stably controlled infection based on viral load.   
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We next used immunofluorescence staining to detect CD103 expressing cells in parallel 
with CD3+ T cells in terminal ileum.  We observed that the majority of CD103 expressing cells 
also expressed CD3 (Fig. 14).  In uninfected macaques, CD103+ cells were localized primarily to 
the subepithelial dome of Peyer’s patches and villa of the terminal ileum.  However, during the 
course of infection, we observed a slight decrease in the density of CD103+ cells in the 
subepithelial dome and intestinal villi (Fig. 14).   
 
Figure 14. CD103+ cells are lost from the subepithelial dome of Peyer’s patches as SIV infection progresses. 
Immunofluorescence staining with anti-CD103 and anti-CD3 antibodies was performed on terminal ileum isolated 
from uninfected and SIV-infected macaques.  Expression of CD103 is visualized in red and CD3 is visualized in 
green.  Isotype control staining is shown in the inset.  CD103+ cells were localized to the villi and subepithelial 
dome region within Peyer’s patches in healthy animals. Cell nuclei (blue) were stained with Hoechst dye.  TSA was 
used to detect anti-CD103 antibody staining.  Images were taken at 200x magnification.  Representative images are 
shown from 2-3 macaques per group.   
 
These findings of lost CD103+ mDC in mesenteric LN and possibly the gut mucosa 
would suggest that, based on findings in mice and humans, Treg differentiated from CD103+ 
mDC in rhesus macaques are also decreased or lost at these sites in response to SIV infection.   
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4.2.5 The proportion of CD141+ mDC increases in mesenteric LN during acute SIV 
infection 
CD141 is a type 1 membrane receptor that denotes mDC with superior antigen cross-presentation 
capacity (122).  At this time, no studies have been published on the role of CD141+ mDC in SIV 
pathogenesis.  Recognizing the possible importance of this subset in controlling viral infections, 
we analyzed the impact of SIV infection and disease status on CD141 expressing mDC.   
Figure 15A indicates positive flow cytometric detection of CD141 on mDC in naïve 
animals as compared to an IgG stained control. 
 
Figure 15. Significant increase in CD141+ mDC during acute but not chronic SIV infection in mesenteric LN. 
(A) Representative flow plots demonstrating expression of CD141 on mDC as compared to an isotype control.  (B) 
Each point represents the percentage of CD141+ mDC in mesenteric (left panel) and peripheral (right panel) LN for 
one animal.  Horizontal lines represent means and * = p<0.05.  UI = uninfected animal.  D14 = day 14 post SIV 
infection.  D36 = day 36 post SIV infection.  D36 +ART = animals started ART on day 7 post SIV infection and 
ended on day 36 post SIV infection.  P = animal that progressed to AIDS based on viral load.  S = animal that stably 
controlled infection based on viral load.   
 
Thirty-seven percent of mDC in mesenteric LN and 54% in peripheral LN from healthy 
macaques expressed CD141.  We observed a significant increase of CD141+ mDC in mesenteric 
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LN and a trend towards significance in peripheral LN from animals with acute SIV infection 
(Fig. 15B).  However, at all later stages of infection in mesenteric and peripheral LN CD141+ 
mDC percentages were roughly equivalent to naïve levels.   
4.2.6 SIV disease status differentially impacts pDC in LN relative to gut 
Loss of pDC in peripheral LN has been associated with HIV/SIV disease progression (152, 154, 
171).  Here we investigated the effect of SIV infection and disease status on pDC proportions in 
peripheral and mesenteric LN.  CD123+ pDC detection as compared to an isotype control is 
shown in Figure 16A.   
 
Figure 16. pDC proportions are modestly decreased in mesenteric and peripheral LN from SIV-infected 
macaques. 
pDC were analyzed within the HLA-DR+Lin- gate (R4) described in Figure 2.  (A) Dot plots represent gating for 
CD123+ pDC as compared to an isotype control.  (B) Percent pDC of total HLA-DR+Lin- cells in mesenteric (left) 
and peripheral (right) LN.  Each point represents one animal and horizontal lines represent means.  * = p<0.05.  UI = 
uninfected animal.  D14 = day 14 post SIV infection.  D36 = day 36 post SIV infection.  D36 +ART = animals 
started ART on day 7 post SIV infection and ended on day 36 post SIV infection.  P = animal that progressed to 
AIDS based on viral load.  S = animal that stably controlled infection based on viral load.  
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Compared to uninfected macaques, pDC proportions were modestly decreased in peripheral LN 
during acute SIV infection and AIDS (Fig. 16B).  We also observed a significantly greater 
proportion of pDC in mesenteric LN from the progressor group compared to stably infected 
animals (Fig. 16B).   
We next sought to determine the impact of SIV infection on CD123+ cell proportions in 
terminal ileum.  Figure 17 displays successful staining for CD123+ cells using a biotinylated 
anti-CD123 antibody.  
 
Figure 17. SIV infection of rhesus macaques results in an influx of CD123+ cells to the gut mucosa. 
Immunofluorescence staining with anti-CD123 antibody was performed on terminal ileum isolated from uninfected 
and acutely and chronically infected macaques.  PFA fixed tissues were sectioned to a thickness of 7µm, stained, 
and visualized by confocal microscopy.  Expression of cell-specific markers is visualized in green.  CD123+ cells 
were seen predominately localized to the submucosa during acute infection and to the lamina propria during chronic 
infection.  Non-specific staining is seen within the crypts and outer lining of the villi in the mucosa.  Differential 
interference contrast light was used to provide texture and delineate mucosa from submucosa regions of ileum from 
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uninfected and acute infected macaques.  Cell nuclei (blue) were stained with Hoechst dye.  TSA was used to detect 
anti-CD123 antibody staining.  Images were taken at 200x magnification and electronically zoomed in.  
Representative images are shown from 2-3 macaques per group. 
 
CD123+ cells appeared to be increased in terminal ileum submucosa during acute SIV infection 
and increased during chronic infection.  Positive staining lining the intestinal crypts and villi of 
the columnar epithelial cells is believed to be anti-CD123 antibody bound non-specifically to 
mucus-secreting goblet cells, which cluster around gut epithelium.  This non-specific staining 
pattern was inconsistently present in the isotype control stained tissue.  
These data show that pDC proportions may be differentially impacted by SIV infection in 
peripheral LN and gut mucosa.  While pDC results in peripheral LN were not significant, their 
trends confirm current knowledge of pDC kinetics in LN in response to HIV/SIV infection (154, 
155, 157).   
4.2.7 Summary of Aim 2 results 
Figures 18 and 19 below display a holistic summary of our findings from Aim 2.  In Figure 18, 
the most robust changes found were with the CD163+ macrophage subset which our data suggest 
are being recruited to LN and possibly gut during SIV infection and disease.  Only minor 
changes in mDC, pDC, and CD163- macrophage proportions were observed throughout each of 
our cohorts, although we did see a trend towards a loss of mDC and pDC in peripheral LN of 
SIV-infected animals compared to healthy uninfected animals.   
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Figure 18. Summary of mDC, pDC, and macrophage proportions in healthy and SIV-infected LN.   
Macrophage and DC subsets from mesenteric (A) and peripheral (B) LN suspensions were gated on as described in 
Figure 2 and calculated as a percent of the HLADR+Lin- population (R4).  Percentages represent means from at least 
three healthy rhesus macaques. 
 
In Figure 19, we summarized our findings described earlier on CD103+ mDC and 
CD141+ mDC in LN from healthy and SIV-infected macaques.  Each subset was detected by 
gating on the CD11c+ mDC population and analyzing for expression of CD103 or CD141 as 
compared to an isotype control (Fig. 2C).  CD103+ mDC were found to be exclusive to 
mesenteric LN, whereas CD141+ mDC were found in mesenteric and peripheral LN.  We 
observed that CD103+ mDC were lost in gut-draining mesenteric LN as SIV infection progressed 
but not in animals that received ART.  In comparison, CD141+ mDC were increased in both 
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mesenteric and peripheral LN during acute stage SIV infection but not during the later stages of 
infection. 
 
Figure 19. Summary of CD103+ and CD141+ mDC proportions in healthy and SIV-infected LN.   
mDC were gated on and analyzed for expression of CD103 and CD141 as described in Figure 2.  mDC subsets 
analyzed from mesenteric (A) and peripheral (B) LN suspensions were calculated as a percent of the HLADR+Lin- 
population (R4).  Percentages represent means from at least three healthy rhesus macaques. 
4.2.8 Preliminary investigation of Treg  
We have demonstrated that CD103+ mDC proportions, shown to be critical modulators of Treg 
differentiation in mice and humans, are progressively lost in mesenteric LN from SIV+ rhesus 
macaques.  As an extension to the aims of this project, based on our CD103+ mDC findings, we 
were encouraged to investigate Treg proportions in mesenteric and peripheral LN from each 
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cohort.  We hypothesized that Foxp3+CD25+ Treg proportions would positively correlate with 
CD103+ mDC levels in mesenteric LN of macaques throughout the different stages of SIV 
infection.   
Figure 20 below diagrams our gating strategy for detection of Foxp3+CD25+ Treg in LN 
suspensions, as well as expression of Ki-67 on Treg cells to determine cellular proliferation.   
 
Figure 20. Representative flow cytometry gating strategy to define Treg in mesenteric and peripheral LN. 
(A) LN cells were gated by forward and side scatter (R1) and live cells were determined based on exclusion of an 
amine reactive dye (R3).  CD3+ cells were then gated (R4) and stained for CD4.  (B) Proportion of CD4+ T cells co-
expressing Foxp3 and CD25 (Treg) as compared to an isotype control.  (C) Proportion of Treg expressing Ki-67 as 
compared to an isotype control. 
 
Figure 21A displays the proportion of Treg detected in peripheral and mesenteric LN from 
uninfected and SIV-infected rhesus macaques calculated as a percentage of the CD4+ population.   
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Figure 21. Treg are lost in peripheral LN of diseased animals, but not mesenteric LN.   
Each point represents the percentage of Treg as detected in Figure 20B (A and B) and Ki-67 as detected in Figure 
20C (C and D) for one animal.  Horizontal lines represent means and * = p<0.05.  UI = uninfected animal.  D14 = 
day 14 post SIV infection.  D36 = day 36 post SIV infection.  D36 +ART = animals started ART on day 7 post SIV 
infection and ended on day 36 post SIV infection.  P = animal that progressed to AIDS based on viral load.  S = 
animal that stably controlled infection based on viral load.   
 
We observed no significant change in the percentage of Foxp3+CD25+ Treg in mesenteric LN in 
response to SIV infection and disease status (Fig. 21A).  Conversely, we found that 
Foxp3+CD25+ Treg were lost from peripheral LN in animals with acute and chronic stages of 
SIV infection, a finding in accord with some previous reports (43, 44, 46).  To determine the 
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percentage of newly proliferated Treg, we stained for Ki-67 in Treg (Fig. 20C).  In mesenteric 
and peripheral LN, shown in Figure 21B, Ki-67 expressing Treg were lost during acute SIV 
infection but seemingly increased to slightly beyond healthy levels at later stages of infection, 
possibly suggesting delayed mobilization of Treg.   
 In summary, these preliminary results show that Treg proportions are not lost in 
mesenteric LN during SIV infection.  This is in contrast with our finding in peripheral LN, in 
which Treg were significantly lost in SIV-infected cohorts as compared to uninfected macaques.  
Based on our findings in Figure 13 that CD103+ mDC are lost in mesenteric LN throughout SIV 
infection, these results could indicate that the link between Treg and CD103+ mDC in macaques 
may be more complex than in humans and mice.   
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5.0  DISCUSSION 
In this study we have addressed some gaps in knowledge of how specialized innate immune cell 
proportions in LN and gut mucosa are impacted by SIV infection and disease status.  These 
results have called attention to the potential significance of specific antigen-presenting cell 
subsets in the pathogenesis of SIV.  Here we examined the impact of SIV infection, disease 
status, and ART on the frequency of macrophage and DC subsets in peripheral LN, mesenteric 
LN, and gut mucosa relative to healthy macaques. 
First, we investigated the effect of SIV disease status and ART on CD163+CD68+ and 
CD163-CD68+ macrophages.  CD163 is a transmembrane protein scavenger receptor reported to 
be present on M2 macrophages, and CD68 is a type 1 transmembrane glycoprotein believed to be 
a pan-macrophage marker (64, 68, 91).  We found that CD68 was expressed by 100% of CD163+ 
macrophages, but was also expressed on a non-overlapping population negative for CD163 
expression.  Putative anti-inflammatory CD163+ macrophage proportions were significantly 
increased in gut-draining mesenteric LN during acute SIV infection and AIDS, which may 
represent a manifestation by the host to attenuate a local or systemic inflammatory response and 
preserve LN integrity.  We also found that CD163+ macrophage proportions were increased in 
peripheral LN of SIV+ animals with acute infection.  Our assumption that CD163+ macrophages 
function to diminish inflammation is based on reports that CD163 denotes M2 macrophages and 
thus will need to be validated in future studies to definitively reach this conclusion.  One study 
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that could be conducted to determine their function would be to stimulate CD163+ macrophages 
sorted by FACS in vitro and assay for the presence or absence of pro- and anti-inflammatory 
cytokines.  Theoretically, rather than serving an anti-inflammatory function, the influx of 
CD163+ macrophages we observed may instead be promoting inflammation.  Intriguingly, we 
found that stably infected SIV+ macaques that did not progress to AIDS had healthy CD163+ 
macrophage levels.  Given that M2 macrophages are more phagocytic than M1 macrophages (61, 
172) and a reasonable cause of chronic immune activation has been attributed to increased levels 
of systemic LPS due to gut microbial translocation (48, 173), it is likely CD163+ macrophages 
are M2-like in function.  Moreover, these findings do correlate with reports of increased CD163+ 
macrophage frequency in plasma with detectable HIV (174) and increased turnover in mesenteric 
LN (82).  In addition, preliminary findings from our lab show CD163+ macrophage proportions 
are increased in bronchoalveolar lavage fluid from SIV-infected macaque lungs (M. Kader).  
Cumulatively, these findings would suggest that this macrophage subset may function to 
attenuate inflammation, not exacerbate it.  In contrast, the fact that we observed no difference in 
the proportion of mesenteric LN CD163-CD68+ macrophages, which may be similar in function 
to intestinal macrophages, shown to be highly phagocytic, CD14 deficient and non-permissive to 
HIV infection, downplays their role in SIV infection, but does not rule out their potential 
importance in providing host protection from or vulnerability to opportunistic infection (85).  We 
also observed no change in CD163-CD68+ macrophage proportions in peripheral LN between 
our cohorts.  However, without more detailed studies, the role and function of CD163-CD68+ 
macrophages, which may represent one or many macrophage subtypes, in mesenteric LN and 
peripheral LN is unclear.  Future studies should clarify these questions.  
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mDC and pDC are widely reported to be lost and dysfunctional in blood during HIV/SIV 
infection, however reports on mDC and pDC in LN are conflicting (150, 167).  Furthermore, 
studies on the role of mDC and pDC in SIV pathogenesis in the gut are lacking.  Our findings on 
mDC and pDC dynamics in LN of healthy and SIV+ rhesus macaques confirm some previous 
reports (154, 155, 157).  We found that SIV disease status differentially impacted mDC and pDC 
proportions in peripheral LN relative to mesenteric LN.  mDC and pDC proportions were 
modestly decreased in peripheral LN during acute and chronic stages of SIV infection, but were 
unaltered in mesenteric LN.  In terminal ileum, we observed an increased density of CD123+ 
cells in macaques with acute and chronic stage SIV infection as compared to uninfected animals.  
Kwa and colleagues recently used flow cytometry to quantitatively demonstrate that pDC are 
recruited to gut mucosa of SIV-infected animals with AIDS and that recruitment and type 1 
interferon immune activation could be reversed by in vivo blockade of α4β7.  Furthermore, this 
reversal of pDC recruitment resulted in decreased T cell proliferation and recruitment to the 
colorectum.  No change in mDC proportions was observed in LN or gut (157).  Nevertheless, the 
roles of mDC and pDC in SIV pathogenesis are still emerging; however based on ours and 
others’ findings it is becoming clear that pDC may be a contributing factor to immune activation 
in the gut and that loss of pDC and mDC in peripheral LN is predictive of disease progression 
(156, 157, 159, 166).   
Next, we explored the influence of SIV infection on CD103 expressing T cells, pDC, and 
mDC in LN and gut mucosa isolated from healthy and SIV-infected macaques.  Recent evidence 
indicates that CD103+ mDC in mice and humans promote mucosal immune regulation by 
stimulating Treg differentiation and imprinting effector T and B cells with gut-homing markers 
CCR9 and α4β7 (108).  T cells have also been shown to express CD103, which is likely 
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important to their retention in the gut (107).  Currently, the role of CD103 expressing cells in SIV 
infection and disease progression is undefined.  In healthy animals, we found CD103 was 
expressed on 2% of CD3+ T cells and 31% of mDC in mesenteric LN, but not on mDC or pDC 
in peripheral LN.  We did not determine the expression level of CD103 on T cells in peripheral 
LN.  CD103+ mDC were dramatically lost by day 14 post SIV infection and continued to be 
depleted in the later stages of infection.  We also observed that this depletion was not present in 
ART treated macaques.  Additionally, a slight decrease in the density of CD103+ cells in Peyer’s 
patches and intestinal villi of terminal ileum as disease progressed was observed; the vast 
majority of which were CD3+ T cells.  Why this subset was not present at healthy levels in 
mesenteric LN from our stably SIV-infected cohort that did not progress to AIDS is unclear but 
could signify a direct or indirect consequence of sustained SIV infection and/or inflammation in 
the gut.  Two studies that looked at the effect of gut inflammatory diseases on CD103+ mDC 
proportions found opposing results; intestinal tissue from Crohn’s disease patients was found to 
have healthy CD103+ mDC levels, whereas mice with colitis had significantly fewer CD103+ 
mDC in their intestine (109, 175).  These findings offer some clues to our observation of a 
sustained loss of CD103+ mDC in mesenteric LN from macaques with and without signs of 
AIDS.  GI problems, such as colitis, are common manifestations in HIV/SIV-infected individuals 
and non-human primates, and thus, at the moment, may explain our results (176).  However, the 
animals separated into the stably infected cohort exhibited no signs of diarrhea or other clinical 
complications associated with AIDS, suggesting there may be a better explanation.  Our finding 
that ART treated macaques had healthy CD103+ mDC levels in mesenteric LN suggest their loss 
may be linked to direct viral infection, which may be inducing cell death.  This hypothesis could 
be validated by staining CD103+ mDC with caspase markers that determine cell death and 
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assaying for SIV in CD103+ mDC by RT-PCR, immunofluorescence, or flow cytometry.  In 
addition to microbial translocation, based on studies conducted in mice and humans on the 
critical nature of CD103+ mDC in driving Treg differentiation and T lymphocyte homing to the 
gut, our findings may suggest one mechanism by which gut immune homeostasis is disrupted 
during SIV infection (108).  
Lastly, we analyzed the impact of SIV disease status on CD141+ mDC.  CD141+ mDC 
have been shown in humans to trigger Th1-centric immune responses (122).  We found that 37% 
of total mDC in mesenteric LN and 54% in peripheral LN from healthy rhesus macaques 
expressed CD141.  In response to SIV infection, CD141+ mDC proportions were significantly 
increased in mesenteric LN and modestly increased in peripheral LN during acute stage 
infection, but were returned to naïve levels during the subsequent post-acute and chronic stages 
of infection.  Lastly, we were unable to detect CD141+ cells by immunofluorescence staining in 
macaque terminal ileum.  The relative contribution of this subset to SIV disease progression is, at 
this time, completely unknown.  Numerous reports have documented that an apparent switch 
from a Th1 cell-mediated immune response to a Th2 humoral immune response underlies AIDS 
onset (177-179).  Interestingly, our findings of increased Th1-inductive CD141+ mDC 
proportions in LN during acute SIV infection, but not during chronic infection, tend towards this 
same interpretation, suggesting that this dynamic may be in part responsible for mediating this 
switch.  However, this theory implies the proportion of CD141+ mDC in stably SIV+ animals 
would be equally as high as those in the acutely infected group, and our data show this is not the 
case.  At this time, we can only speculate about the role of CD141+ mDC in SIV pathogenesis 
when so little is known phenotypically and functionally about this subset in rhesus macaques. 
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As an extension to the aims of this thesis, our CD103+ mDC findings prompted us to 
undertake a preliminary investigation of Treg in our healthy and SIV-infected cohorts.  The loss 
of CD103+ mDC proportions in mesenteric LN we observed would suggest a correlating loss of 
Treg based on CD103+ mDC functional reports in humans and mice (108, 111).  Surprisingly, no 
change was observed in the proportion of Foxp3+CD25+ Treg in mesenteric LN from SIV-
infected animals relative to controls, but we did see a significant decrease in peripheral LN Treg 
proportions at acute and chronic stages of infection.  These findings are confounding.  The 
function of CD103+ mDC in rhesus macaques is undefined, and consequently, the meaning and 
implications of decreased CD103+ mDC frequency in mesenteric LN during SIV infection are 
unclear.  On the surface our data would suggest there is no correlation between CD103+ mDC 
and Treg in rhesus macaques in response to SIV infection.  Presecci and colleagues recently 
demonstrated that mDC sorted by FACS from mesenteric LN of SIV-infected animals with 
AIDS and cultured with autologous CD4+ T cells promoted Treg induction better than mDC 
from healthy animals.  However, they observed that CD103 expression was reduced on the same 
sorted mDC population from AIDS animals compared to controls, which they concluded 
suggests CD103 expression does not correlate with Treg induction (180).  A more definitive 
study we hope to conduct in the future would be to sort CD103+ mDC from mesenteric LN of 
healthy and SIV+ macaques, culture those cells with autologous naïve CD4+ T cells, and assay 
for Foxp3 expression by flow staining.   
Taken together, this work provides a cross-sectional analysis of the proportions of 
macrophage and DC subsets in tissues from uninfected and SIV+ macaques sacrificed at different 
stages of infection.  Our results align with models of excessive immune activation in LN and the 
GI tract due to HIV/SIV infection and possibly, in part, may suggest a mechanism behind this 
 57 
phenomenon (48, 181).  We found that CD123+ cells, which have been shown to be chronically 
activated in HIV/SIV studies and correlated with disease progression (157, 164), were increased 
in density in the gut as infection progressed, supporting studies that suggest they may promote 
intestinal inflammation.  Conversely, our finding of increased anti-inflammatory CD163+ 
macrophage proportions in mesenteric LN and gut alludes to a counter-attempt by the host to 
attenuate an inflammatory response.  Lastly, SIV-infected rhesus macaques had significantly 
lower Treg-driving CD103+ mDC proportions as compared to healthy uninfected macaques, 
which may be a contributing factor to loss of gut immune homeostasis.  Unfortunately, our Treg 
findings in LN complicate this model; however some evidence suggests Treg proportions are 
significantly depleted in gut during SIV infection (42).  In the future we aim to quantify Treg in 
gut tissues from our cohorts.   
As with all research, there are limitations to this study.  One limitation of this study was 
its inability to demonstrate cause-and-effect.  A longitudinal study design would have been a 
better way to demonstrate the effects of infection overtime and establish causality.   
Importantly, these studies highlight the impact of SIV infection on innate immune cells in 
LN and gut mucosa and point to their potential contributions in virus control and chronic 
immune activation.  Continued research on the role of macrophages and DC in SIV pathogenesis 
could bolster strategies to design novel anti-HIV therapeutics that dually target the viral life 
cycle and the innate immune response, and thus have significant public health value.  Further 
studies towards elucidating the impact of disease on macrophages and DC are critical to 
understanding the complexity of the immune response to HIV/SIV infection.  
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